Doliver Advisors LP Sells 70,000 Shares of BioCryst Pharmaceuticals, Inc. $BCRX

Doliver Advisors LP trimmed its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 18.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 304,328 shares of the biotechnology company’s stock after selling 70,000 shares during the quarter. BioCryst Pharmaceuticals comprises about 0.5% of Doliver Advisors LP’s investment portfolio, making the stock its 28th largest holding. Doliver Advisors LP’s holdings in BioCryst Pharmaceuticals were worth $2,535,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Bank of America Corp DE grew its position in shares of BioCryst Pharmaceuticals by 231.6% during the 1st quarter. Bank of America Corp DE now owns 5,091,765 shares of the biotechnology company’s stock worth $48,474,000 after purchasing an additional 3,556,208 shares in the last quarter. Pacer Advisors Inc. acquired a new stake in BioCryst Pharmaceuticals during the first quarter worth approximately $14,880,000. Wedge Capital Management L L P NC bought a new position in shares of BioCryst Pharmaceuticals in the second quarter worth $3,808,000. ADAR1 Capital Management LLC acquired a new position in shares of BioCryst Pharmaceuticals in the 2nd quarter valued at approximately $1,330,000. Finally, Perceptive Advisors LLC raised its position in BioCryst Pharmaceuticals by 135.1% during the first quarter. Perceptive Advisors LLC now owns 7,434,033 shares of the biotechnology company’s stock valued at $70,772,000 after purchasing an additional 4,271,504 shares in the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX traded down $0.21 during midday trading on Thursday, hitting $8.12. 5,785,302 shares of the company traded hands, compared to its average volume of 4,882,365. The stock has a 50-day moving average of $9.28 and a 200-day moving average of $9.25. The firm has a market cap of $2.07 billion, a P/E ratio of -5.41 and a beta of 0.57. BioCryst Pharmaceuticals, Inc. has a one year low of $6.00 and a one year high of $11.22.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share for the quarter, topping the consensus estimate of $0.15 by $0.15. The company had revenue of $218.25 million for the quarter, compared to analysts’ expectations of $183.28 million. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. BioCryst Pharmaceuticals’s revenue for the quarter was up 33.6% compared to the same quarter last year. During the same period in the prior year, the business earned $0.15 earnings per share. Sell-side analysts forecast that BioCryst Pharmaceuticals, Inc. will post -2.25 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on BCRX shares. JPMorgan Chase & Co. boosted their target price on shares of BioCryst Pharmaceuticals from $12.00 to $13.00 and gave the stock a “neutral” rating in a research note on Wednesday. Weiss Ratings lowered BioCryst Pharmaceuticals from a “hold (c)” rating to a “sell (d-)” rating in a research report on Tuesday, September 22nd. Wedbush reduced their price target on shares of BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Needham & Company LLC reissued a “buy” rating and issued a $16.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, September 8th. Finally, Wall Street Zen downgraded BioCryst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 29th. Seven research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $20.50.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes oral medicines for rare diseases. The company focuses on small-molecule therapies designed to address diseases with significant unmet medical needs, including hereditary angioedema and complement-mediated disorders.

BioCryst’s primary commercial product is Orladeyo (berotralstat), an oral plasma kallikrein inhibitor used to prevent attacks of hereditary angioedema in adults and pediatric patients.